Article Sidebar

PDF
Date Published: 06/11/2023
Online Published: 06/11/2023
Abstract Views: 293
Views PDF: 190
DOI: https://doi.org/10.58490/ctump.2023i67.2188
Issue
No. 67 (2023)
Section
Article
How to Cite
Nguyen, T. V., Vo, P. M. T., Tran, C. D., & Phan, V. H. (2023). METHICILLIN-RESISTANT STAPHYLOCOCCAL PNEUMONIA: A REVIEW OF PATHOLOGY AND PHARMACOLOGICAL THERAPY. Cantho Journal of Medicine and Pharmacy, 67, 105-114. https://doi.org/10.58490/ctump.2023i67.2188

METHICILLIN-RESISTANT STAPHYLOCOCCAL PNEUMONIA: A REVIEW OF PATHOLOGY AND PHARMACOLOGICAL THERAPY

Thien Vu Nguyen1,, Pham Minh Thu Vo2, Cong Dang Tran2, Viet Hung Phan2
1 Can Tho University of Medicine and Pharmacy Hospital
2 Can Tho University of Medicine and Pharmacy

Main Article Content

Abstract

Methicillin-resistant Staphylococcus aureus (MRSA), which is not a prevelant pathogen, tends to emerge and plays an vital role in severe pneumonia with many complications and high mortality. Assessing the risk of MRSA infection is an important practice while deciding the antibiotic choice in pneumonia patients (including severe community-acquired pneumonia and hospitalacquired pneumonia). In patients at high risk or with evidence of MRSA infection, vancomycin and linezolid are the first-line treatment options. Each drug has its own advantages and disadvantages in terms of pharmacokinetics and pharmacodynamics. Neither of drug is superior in terms of effectiveness and safety in treating pneumonia than the other, requiring careful monitoring and evaluating to optimize treatment for individuals. Some new antibiotics, such as 5th generation cephalosporins, may be potential antibiotic of choices for treating MRSA pneumonia in the future.

Article Details

Keywords

MRSA, pneumnia, pharmacological therapy

References

1. Rogers D.E., Kasper D.L., Braunwald E., Staphylococcal infections, Harrison's principles of internal medicine 20th edition, 1(5). 2018. 1071-1081.
2. Nguyễn Thanh Bảo, Cao Minh Nga, Trần Thị Thanh Nga, và cộng sự, Chọn lựa kháng sinh ban đầu trong điều trị nhiễm khuẩn bệnh viện tại một số bệnh viện TP HCM, Tạp Chí Y học TP HCM, chuyên đề Nội Khoa II, 2012, 16(1), tr. 206-214.
3. File, T. M., Jr, & Ramirez, J. A. (2023). Community-Acquired Pneumonia. The New England journal of medicine, 389(7), 632–641. https://doi.org/10.1056/NEJMcp2303286.
4. Esposito S, Blasi F, Curtis N, et al. New Antibiotics for Staphylococcus aureus Infection: An
Update from the World Association of Infectious Diseases and Immunological Disorders (WAidid) and the Italian Society of Anti-Infective Therapy (SITA). Antibiotics (Basel). 2023;12(4):742. Published 2023 Apr 12. doi:10.3390/antibiotics12040742.
5. Peto, L., Nadjm, B., Horby, P., Ngan, T. T., van Doorn, R., Van Kinh, N., & Wertheim, H. F. (2014). The bacterial aetiology of adult community-acquired pneumonia in Asia: a systematic review. Transactions of the Royal Society of Tropical Medicine and Hygiene, 108(6), 326–337. https://doi.org/10.1093/trstmh/tru058.
6. Lee LN, Chou WR, Wang JY, et al. Characteristics and local risk factors of communityacquired and health-care-associated Staphylococcus aureus pneumonia. Sci Rep. 2022;12(1):18670. Published 2022 Nov 4. doi:10.1038/s41598-022-23246-1.
7. Kalil, A. C., Metersky, M. L., Klompas, M., Muscedere, J., Sweeney, D. A et al. (2016). Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 63(5), e61–e111. https://doi.org/10.1093/cid/ciw353.
8. Võ Phạm Minh Thư, Trần Công Đăng, Phan Việt Hưng, Cao Thị Mỹ Thúy, Nguyễn Thị Diệu Hiền và cộng sự (2023). Khảo sát đặc điểm lâm sàng, cận lâm sàng và kết quả điều trị bệnh nhân viêm phổi do Staphylococcus aureus . Tạp chí Y Dược học Cần Thơ, 62, 135-141.
9. Welte, T., & Pletz, M. W. (2010). Antimicrobial treatment of nosocomial meticillin-resistant Staphylococcus aureus (MRSA) pneumonia: current and future options. International journal of antimicrobial agents, 36(5), 391–400. https://doi.org/10.1016/j.ijantimicag.2010.06.045.
10. Rybak, M. J., Le, J., Lodise, T. P., Levine, D. P., Bradley, J. S., Liu, et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2020. 77(11), 835–864. https://doi.org/10.1093/ajhp/zxaa036.
11. Jacob, J. T., & DiazGranados, C. A. (2013). High vancomycin minimum inhibitory concentration and clinical outcomes in adults with methicillin-resistant Staphylococcus aureus infections: a metaanalysis. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 17(2), e93–e100. https://doi.org/10.1016/j.ijid.2012.08.005.
12. Wang J, Xia L, Wang R, Cai Y. Linezolid and Its Immunomodulatory Effect: In Vitro and In Vivo Evidence. Front Pharmacol. 2019;10:1389. Published 2019 Nov 28. doi:10.3389/fphar.2019.01389.
13. Wang, Y., Zou, Y., Xie, J., Wang, T., Zheng, X., He, H., Dong, W., Xing, J., & Dong, Y. (2015). Linezolid versus vancomycin for the treatment of suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a systematic review employing meta-analysis. European journal of clinical pharmacology, 71(1), 107–115. https://doi.org/10.1007/s00228-014-1775-x.